Zim Laboratories' Q1 FY 2025-26 Quarterly Results
- 08 Aug 2025
Result Summary
- Zim Laboratories Ltd reported a 38.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.6%.
- Its expenses for the quarter were down by 30.2% QoQ and 7.3% YoY.
- The net profit decreased 123.1% QoQ and decreased 307.8% YoY.
- The earnings per share (EPS) of Zim Laboratories Ltd declined at 0.4 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
Total Income | 73.23 | 119.40 | 82.82 | -38.7% | -11.6% |
Total Expenses | 75.66 | 108.41 | 81.59 | -30.2% | -7.3% |
Profit Before Tax | -2.43 | 11.00 | 1.23 | -122.1% | -297.6% |
Tax | -0.56 | 2.91 | 0.34 | -119.2% | -264.7% |
Profit After Tax | -1.87 | 8.09 | 0.90 | -123.1% | -307.8% |
Earnings Per Share | -0.40 | 1.70 | 0.20 | -123.5% | -300.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zim Laboratories Ltd is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical products. The company is primarily involved in the formulation and production of drugs, with a focus on novel drug delivery solutions. Their portfolio includes oral solid dosage forms, taste-masked products, and other innovative drug delivery systems. Zim Laboratories serves various markets, including domestic and international segments, catering to a diverse clientele. As of the latest updates available before October 2023, the company has been actively involved in expanding its product range and enhancing its manufacturing capabilities. Any further specific developments or strategic shifts post this period are not available for analysis.
Revenue
In Q1FY26, Zim Laboratories Ltd reported a total income of ₹73.23 crores, reflecting a significant quarter-over-quarter (QoQ) decrease of 38.7% compared to the previous quarter, Q4FY25, which recorded a total income of ₹119.40 crores. On a year-over-year (YoY) basis, total income showed a decrease of 11.6% from ₹82.82 crores in Q1FY25. The decline in revenue both sequentially and annually indicates variations in the company's sales performance over the specified periods. The changes in revenue can be attributed to various market dynamics and operational factors that are not specified in the provided data.
Profitability
The profitability metrics for Zim Laboratories Ltd in Q1FY26 demonstrate a challenging financial period. The company recorded a loss with a profit before tax (PBT) of ₹-2.43 crores, compared to a profit of ₹11.00 crores in Q4FY25. This marks a QoQ decline of 122.1% in PBT. On a YoY basis, PBT also decreased by 297.6% from ₹1.23 crores in Q1FY25. The profit after tax (PAT) followed a similar trend, with a negative figure of ₹-1.87 crores in Q1FY26, down from ₹8.09 crores in Q4FY25. This represents a QoQ change of -123.1% and a YoY change of -307.8% from ₹0.90 crores in Q1FY25. Earnings per share (EPS) was reported at ₹-0.40 for Q1FY26, showing a substantial decline of 123.5% QoQ from ₹1.70 in Q4FY25 and a 300.0% decrease YoY from ₹0.20 in Q1FY25.
Operating Metrics
The total expenses for Zim Laboratories Ltd in Q1FY26 amounted to ₹75.66 crores, which is a reduction of 30.2% from ₹108.41 crores in Q4FY25. Compared to the same quarter in the previous year, Q1FY25, where expenses were ₹81.59 crores, there is a YoY decrease of 7.3%. The reduction in expenses both on a quarterly and annual basis highlights changes in the company's cost structure over the analyzed periods. The financial data provided does not include specific details on operational changes or strategic initiatives that may have influenced these metrics.